Literature DB >> 26739484

Immediate post-procedure bridging with unfractioned heparin versus low molecular weight heparin in patients undergoing radiofrequency ablation for atrial fibrillation with an interrupted oral anticoagulation strategy.

Gerard Loughlin1, Tomás Datino Romaniega2, Javier Garcia-Fernandez3, David Calvo4, Ricardo Salgado3, Andres Alonso1, Xin Li1, Angel Arenal1, Esteban González-Torrecilla1, Felipe Atienza1, Francisco Fernández-Avilés1.   

Abstract

PURPOSE: Many centers perform catheter ablation for atrial fibrillation (AF) with periprocedural interruption of oral vitamin K antagonists. In this scenario, the optimal post-procedural anticoagulation strategy is still under debate. We sought to compare the incidence of major complications associated with post-procedural use of low molecular weight heparin (LMWH) versus unfractioned heparin (UFH) as a bridge to reinitiation of oral anticoagulation after an AF ablation procedure.
METHODS: We retrospectively reviewed medical history data of all patients undergoing catheter ablation for AF at three Spanish referral centers between January 2009 and January 2014. A total of 702 patients were included in the analysis. We compared the incidence of major complications (a combination of major bleeding and thromboembolic events) between patients receiving UFH (291) and those receiving LMWH (411) after the procedure.
RESULTS: The overall incidence of major complications was 4.1%, including five thromboembolic events (0.7%) and 24 major bleeding events (3.4%), with no significant differences in patients treated with LMWH vs. UFH (2.9 vs. 4.1%; P = NS). The presence of peripheral vascular disease emerged as the only independent predictor of major complications (adjusted odds ratio (OR) 9.1; confidence interval (CI) 95% 1.7-49.3; P < 0.01).
CONCLUSIONS: Immediate post-procedural bridging with UFH or with LMWH are equally safe strategies in patients undergoing catheter ablation for AF in whom oral anticoagulation is interrupted for the procedure. Due to its greater simplicity of use, LMWH may be the preferred option. The presence of peripheral vascular disease is a potent predictor of major post-procedural complications.

Entities:  

Keywords:  Anticoagulation; Atrial fibrillation; Heparin; Protamine; Radiofrequency ablation

Mesh:

Substances:

Year:  2016        PMID: 26739484     DOI: 10.1007/s10840-015-0098-x

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  26 in total

1.  Radiofrequency catheter ablation: different cooled and noncooled electrode systems induce specific lesion geometries and adverse effects profiles.

Authors:  Uwe Dorwarth; Michael Fiek; Thomas Remp; Cristopher Reithmann; Martin Dugas; Gerhard Steinbeck; Ellen Hoffmann
Journal:  Pacing Clin Electrophysiol       Date:  2003-07       Impact factor: 1.976

2.  Uninterrupted warfarin anticoagulation for atrial fibrillation ablation: too good to be true?

Authors:  Roger A Winkle
Journal:  Pacing Clin Electrophysiol       Date:  2014-04-26       Impact factor: 1.976

3.  Risk predictors of stroke and mortality after ablation for atrial fibrillation: the California experience 2005-2009.

Authors:  Uma N Srivatsa; Beate Danielsen; Ivan Anderson; Ezra Amsterdam; Nayereh Pezeshkian; Yingbo Yang; Richard H White
Journal:  Heart Rhythm       Date:  2014-07-15       Impact factor: 6.343

4.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

5.  A focal source of atrial fibrillation treated by discrete radiofrequency ablation.

Authors:  P Jaïs; M Haïssaguerre; D C Shah; S Chouairi; L Gencel; M Hocini; J Clémenty
Journal:  Circulation       Date:  1997-02-04       Impact factor: 29.690

6.  Embolic events and char formation during pulmonary vein isolation in patients with atrial fibrillation: impact of different anticoagulation regimens and importance of intracardiac echo imaging.

Authors:  Oussama M Wazni; Antonio Rossillo; Nassir F Marrouche; Eduardo B Saad; David O Martin; Mandeep Bhargava; Dianna Bash; Salwa Beheiry; Mark Wexman; Domenico Potenza; Ennio Pisano; Raffaele Fanelli; Aldo Bonso; Sakis Themistoclakis; Demet Erciyes; Walid I Saliba; Robert A Schweikert; Johannes Brachmann; Antonio Raviele; Andrea Natale
Journal:  J Cardiovasc Electrophysiol       Date:  2005-06

7.  Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: a safe and efficacious periprocedural anticoagulation strategy.

Authors:  Ayman A Hussein; David O Martin; Walid Saliba; Deven Patel; Saima Karim; Omar Batal; Mustafa Banna; Michelle Williams-Andrews; Minerva Sherman; Mohamed Kanj; Mandeep Bhargava; Thomas Dresing; Thomas Callahan; Patrick Tchou; Luigi Di Biase; Salwa Beheiry; Bruce Lindsay; Andrea Natale; Oussama Wazni
Journal:  Heart Rhythm       Date:  2009-07-10       Impact factor: 6.343

8.  Left atrial "stunning" following radiofrequency catheter ablation of chronic atrial flutter.

Authors:  P B Sparks; S Jayaprakash; J K Vohra; H G Mond; A G Yapanis; L E Grigg; J M Kalman
Journal:  J Am Coll Cardiol       Date:  1998-08       Impact factor: 24.094

9.  Incidence and predictors of periprocedural cerebrovascular accident in patients undergoing catheter ablation of atrial fibrillation.

Authors:  Daniel Scherr; Kavita Sharma; Darshan Dalal; David Spragg; Karuna Chilukuri; Alan Cheng; Jun Dong; Charles A Henrikson; Saman Nazarian; Ronald D Berger; Hugh Calkins; Joseph E Marine
Journal:  J Cardiovasc Electrophysiol       Date:  2009-12

10.  Safety and convenience of continuous warfarin strategy during the periprocedural period in patients who underwent catheter ablation of atrial fibrillation.

Authors:  Jae-Jin Kwak; Hui-Nam Pak; Jin-Kun Jang; Sook Kyoung Kim; Jae Hyung Park; Jong-Il Choi; Chun Hwang; Young-Hoon Kim
Journal:  J Cardiovasc Electrophysiol       Date:  2009-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.